Why the study?
Some studies describe that certain tyrosine kinase inhibitors are associated with changes in the glycemic profile of patients, but this effect in clinical practice remains unclear.
Does treatment with tyrosine kinase inhibitors affect serum glucose levels in diabetic and nondiabetic patients?
Does treatment with tyrosine kinase inhibitors affect serum glucose levels in diabetic and nondiabetic patients?
Tyrosine kinase inhibitors do not appear to significantly alter serum glucose levels in clinical practice, contrary to some previous literature.
CONTEXT: Tyrosine kinase inhibitors (TKIs) are used in different types of cancers due to their good profile of adverse reactions and their convenience in the oral administration. Some studies describe that certain TKIs are associated with changes in the glycemic profile of the patients. AIMS: This study aims to determine if treatment with ITK affects to serum glucose levels in clinical practice. SETTINGS AND DESIGN: A retrospective study was carried out in 136 episodes (112 patients treated with sorafenib, sunitinib, imatinib, dasatinib, or nilotinib). SUBJECTS AND METHODS: The serum glucose levels were analyzed before treatment and after months 1, 2, 3, 6, 9, and 12 of treatment. STATISTICAL ANALYSIS USED: Statistical analysis was completed with SPSS version 20 for Windows. RESULTS: There were significant differences in the serum glucose levels before treatment between diabetic and nondiabetic patients, but not between the average blood glucose readings before treatment and the average of the subsequent readings, once their treatment had begun. CONCLUSIONS: The results of this study do not reproduce the results of the literature since changes in the serum glucose levels have not been found in this sample of patients.
No takes yet. Share an insight, caveat, or question.
Romero‐Ventosa et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: